Literature DB >> 28299974

Causes of peripheral cytopenia in hepatitic cirrhosis and portal hypertensive splenomegaly.

Yunfu Lv1, Wan Yee Lau1,2, Hongfei Wu1, XiaoYu Han1, Xiaoguang Gong1, Ning Liu1, Jie Yue1, Qingqing Li1, YeJuan Li1, Jie Deng1.   

Abstract

The clinical data of 183 patients with hepatitic cirrhosis and portal hypertensive splenomegaly complicated by peripheral cytopenia were retrospectively analyzed to investigate the causes of peripheral cytopenia, as well as the proportion of the causes in these patients. All patients underwent splenectomy. Before operation, these patients had one or more types of peripheral cytopenia (cumulative cytopenia: 390 patient-times). After splenectomy, blood counts in 79.2% (309/390) returned to normal, while in 15.9% (62/390) they increased but failed to reach to normal levels, and in 4.9% (19/390) they became lower than before the operations. For the last group of patients ( n = 19), long-term follow-up showed that blood counts returned to normal in five patients. In other words, in 80.5% [(309 + 5)/390 or 314/390] of patient-times, the peripheral cytopenia was due to hypersplenism, in 15.9% it was due to a combination of factors, and in 3.6% [14/390] it had nothing to do with the hypersplenism. Thus, hypersplenism is a major cause, but not the only cause, of peripheral cytopenia in patients with hepatic cirrhosis and portal hypertensive splenomegaly, and splenectormy is an effective treatment for these patients. Impact statement For a long time, the development of peripheral cytopenias as a complication to cirrhotic portal hypertension has been attributed to hypersplenism; however, this has never been fully demonstrated. Dameshek summarized that hypersplenism should be diagnosed by the presence of four conditions: (a) mono- or multi-lineage peripheral cytopenias; (b) compensatory hyperplasia of bone marrow; (c) splenomegaly; and (d) correction of cytopenias after splenectomy. We retrospectively analyzed the clinical data from 183 surgical patients, and found that 80.5% of peripheral cytopenias was caused by hypersplenism, 16% by a combination of factors, and 3.5% by other factors unrelated to hypersplenism. As the first quantitative findings in this field, our results verify that hypersplenism is a major, but not exclusive, cause of peripheral cytopenias, and provides important clinical evidence for investigating the cause of peripheral cytopenias.

Entities:  

Keywords:  Portal hypertension; causes; hypersplenism; other factors; peripheral cytopenia

Mesh:

Year:  2017        PMID: 28299974      PMCID: PMC5363688          DOI: 10.1177/1535370217693113

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  48 in total

1.  [Clinical features and laboratory findings of adult Epstein-Barr virus associated T/NK lymphoproliferative disease].

Authors:  Qian Zhang; Hong-Yu Zhang; Wen-Li Zhang; Feng-Luan Zhong; Jia Feng; Qing-Xiang Meng; Wei-Hua Yin; Li-Ping Nie
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2013-08

2.  Platelet autoantibodies in patients with chronic liver disease.

Authors:  J Pereira; L Accatino; J Alfaro; J Brahm; P Hidalgo; D Mezzano
Journal:  Am J Hematol       Date:  1995-11       Impact factor: 10.047

3.  A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.

Authors:  M Wasif Saif; Adam M Lee; Steven M Offer; Kathleen McConnell; Valerie Relias; Robert B Diasio
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

Review 4.  Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients.

Authors:  Gennaro D'Amico; Luigi Pagliaro; Giada Pietrosi; Ilaria Tarantino
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

5.  Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab.

Authors:  Suresh K Krishnan; Anita Hill; Peter Hillmen; Louise M Arnold; Gemma L Brooksbank; Alex Wood; Andrew Scarsbrook; Mervyn H Davies; Richard J Kelly
Journal:  Int J Hematol       Date:  2013-10-25       Impact factor: 2.490

6.  Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients.

Authors:  Gisèle N'Kontchou; Olivier Seror; Valérie Bourcier; Djamila Mohand; Yves Ajavon; Laurent Castera; Véronique Grando-Lemaire; Nathalie Ganne-Carrie; Nicolas Sellier; Jean-Claude Trinchet; Michel Beaugrand
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 2.566

7.  Hemodynamic effects of combined therapy using partial splenic embolization and transjugular retrograde obliteration for gastric varices with gastrorenal shunt.

Authors:  Fumio Chikamori; Atsushi Inoue; Hiroshi Okamoto; Nobutoshi Kuniyoshi; Takahiko Kawashima; Yasuhiro Takase
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

8.  [Endoscopic ligation in treatment of advanced schistosomiasis patients with esophageal variceal bleeding: a report of 68 cases].

Authors:  Pei-Xiang Liu; Guo-Qing Kong
Journal:  Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi       Date:  2013-02

9.  Beta-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease.

Authors:  N Singh; V L Yu; L A Mieles; M M Wagener
Journal:  Am J Med       Date:  1993-03       Impact factor: 4.965

10.  Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity.

Authors:  Federica Barzaghi; Laura Passerini; Rosa Bacchetta
Journal:  Front Immunol       Date:  2012-07-31       Impact factor: 7.561

View more
  16 in total

1.  Relationship between splenomegaly and transfusion requirements in patients with cirrhosis.

Authors:  Christopher H Tan; James A Hall; Kendall Hammonds; Jyothi Dodlapati; Walter J Linz; Sherronda M Henderson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-09-02

2.  Correlation of postoperative splenic volume increase with prognosis of hepatocellular carcinoma after curative hepatectomy

Authors:  Jian Lin; Min-Hui Chi; Xiang Zhang; Shan-Geng Weng
Journal:  Can J Surg       Date:  2019-12-01       Impact factor: 2.089

3.  Single-cell RNA Sequencing Analysis Reveals New Immune Disorder Complexities in Hypersplenism.

Authors:  Hai-Chao Zhao; Chang-Zhou Chen; Huang-Qin Song; Xiao-Xiao Wang; Lei Zhang; Hao-Liang Zhao; Jie-Feng He
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

4.  Cirrhosis in Wilson Disease is characterized by Impaired Hepatic Synthesis, Leukopenia and Thrombocytopenia.

Authors:  Hao-Jie Zhong; Ping Xiao; Da Lin; Hui-Min Zhou; Xing-Xiang He
Journal:  Int J Med Sci       Date:  2020-05-29       Impact factor: 3.738

5.  Radiotherapy for one rectal cancer patient with cirrhosis and moderate to severe thrombocytopenia: a case report.

Authors:  Xinqi Shi; Huifang Xia; Weiwei Zhang; Guang Li; Ailin Li
Journal:  Onco Targets Ther       Date:  2018-08-27       Impact factor: 4.147

6.  Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance.

Authors:  Xiaoyu Han; Yunfu Lv; Yejuan Li; Jie Deng; Qingan Qiu; Ning Liu; Shuya Zhao; Caixian Liao
Journal:  J Int Med Res       Date:  2018-05-20       Impact factor: 1.671

7.  Hyperactive Follicular Helper T Cells Contribute to Dysregulated Humoral Immunity in Patients With Liver Cirrhosis.

Authors:  Juanjuan Zhao; Jijing Shi; Mengmeng Qu; Xin Zhao; Hongbo Wang; Man Huang; Zhenwen Liu; Zhiwei Li; Qing He; Shuye Zhang; Zheng Zhang
Journal:  Front Immunol       Date:  2019-08-13       Impact factor: 7.561

8.  Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease.

Authors:  Bernhard Scheiner; Georg Semmler; Florian Maurer; Philipp Schwabl; Theresa A Bucsics; Rafael Paternostro; David Bauer; Benedikt Simbrunner; Michael Trauner; Mattias Mandorfer; Thomas Reiberger
Journal:  Liver Int       Date:  2019-09-13       Impact factor: 5.828

9.  Hematological Indices in Portal Hypertension: Cirrhosis versus Noncirrhotic Portal Hypertension.

Authors:  Abdurrahman Sahin; Hakan Artas; Nurettin Tunc; Mehmet Yalniz; Ibrahim Halil Bahcecioglu
Journal:  J Clin Med       Date:  2018-08-02       Impact factor: 4.241

10.  Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis.

Authors:  Hanxiao You; Linyi Peng; Jiuliang Zhao; Yunyun Fei; Qian Wang; Wen Zhang; Mengtao Li; Xiaofeng Zeng
Journal:  J Immunol Res       Date:  2020-05-21       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.